[7/7]
WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ
(COVID-19 Global Epidemiological Update )
Coronavirus Disease 2019 (COVID-19) µ¿Çâ Highlights
COVID-19 ±¹Á¦ ÇöȲ(Global Overview)
-2020³â 10¿ù ÀÌÈÄ °¡Àå ³·Àº »ç¸Á·ü º¸°í-
±Û·Î¹ú Äڷγª19 ½Å±Ô È®ÁøÀÚ ¼ö´Â ¼ÒÆø Áõ°¡ÇÑ ¹Ý¸é, ½Å±Ô »ç¸ÁÀÚ ¼ö´Â °è¼Ó °¨¼ÒÇÏ¿© Àü ¼¼°èÀûÀ¸·Î 260¸¸°ÇÀÌ ³Ñ´Â ½Å±Ô »ç·Ê¿Í 54,000¸í ¹Ì¸¸ÀÇ ½Å±Ô »ç¸ÁÀÚ°¡ Áö³ÁÖ¿¡ º¸°í µÇ¾ú´Ù(6¿ù28~7¿ù4ÀÏ, 2021³â Åë°è). ÀÌ´Â 2020³â 10¿ù ÀÌ·¡·Î °¡Àå ³·Àº ÁÖ°£ »ç¸Á·üÀÌ´Ù(±×¸² 1). 2021³â 7¿ù 4ÀÏÀÚ WHO´Â Àü ¼¼°èÀûÀ¸·Î COVID-19 °¨¿° È®ÁøÀÚ ´©Àû»ç·Ê, 1¾ï 8,300¸¸°ÇÀ» ÃÊ°úÇÏ¿´°í »ç¸ÁÀÚ ¼ö´Â 400¸¸¸íÀ» À°¹ÚÇÏ°í ÀÖÀ½À» º¸°íÇÏ¿´´Ù.
±×¸² 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 4 July 2021
Áö³ÁÖ ¾Æ¸Þ¸®Ä«¸¦ Á¦¿ÜÇÑ ¸ðµç Áö¿ªÀº ½Å±Ô»ç·Ê Áõ°¡¸¦ º¸°íÇß´Ù. À¯·´ ??Áö¿ªÀº ¹ßº´·üÀÌ 30% ±Þ°ÝÈ÷ Áõ°¡ÇÑ ¹Ý¸é¿¡, ¾ÆÇÁ¸®Ä« Áö¿ªÀº 23% »ç¸Á·üÀ» º¸°íÇß´Ù. ¹ÌÁÖ¿Í µ¿³²¾Æ½Ã¾Æ¸¦ Á¦¿ÜÇÑ ¸ðµç Áö¿ª¿¡¼ Áö³ÁÖ¿¡ ºñ±³ÇÏ¿© »ç¸ÁÀÚ°¡ Áõ°¡Çß´Ù.
°¡Àå ³ôÀº ½Å±Ô È®ÁøÀÚ´Â ºê¶óÁú(364709¸í), Àεµ(312,250¸í), ÄÝ·Òºñ¾Æ(204,556¸í), Àεµ³×½Ã¾Æ(168,780¸í),°ú ¿µ±¹(161,805¸í)À¸·Î º¸°íµÇ¾ú´Ù.
±¹Á¦Àû º¯À̹ÙÀÌ·¯½º È®»ê°ú °ü·ÃÇÏ¿© Àü¼¼°èÀûÀ¸·Î ¾ËÆÄ º¯ÀÌÀÇ »ç·Ê´Â 173°³ ±¹°¡, º£Å¸º¯ÀÌ 122°³ ±¹°¡(3°³ »õ·Î¿î ±¹°¡), µ¨Å¸º¯ÀÌ 104°³ ±¹°¡(7°³ »õ·Î¿î ±¹°¡), °¨¸¶º¯ÀÌ 74°³±¹°¡(2°³ »õ·Î¿î ±¹°¡)¿¡¼ º¸°íµÇ¾ú´Ù(±×¸² 4). À̹ø ¹öÀü¿¡¼´Â VOCÀÇ Ç¥ÇöÇü Ư¼º(ÀüÆļº, Áúº´½É°¢µµ, Àç°¨¿° À§Çè, Áø´Ü ¹× ¹é½Å È¿´É ¿µÇâ)¿¡ °ü·ÃµÈ »õ·Î¿î ¾÷µ¥ÀÌÆ®, Áö¸®Àû ºÐÆ÷¿¡ ´ëÇÑ ¾÷µ¥ÀÌÆ® ¹× º¯ÀÌ¿¡ ´ëÇØ ÃÊÁ¡À» µÎ¾ú´Ù. VOCs ¹× º¯ÀÌ ºÐ·ù, ¸ð´ÏÅ͸µÁßÀÎ ¾Æ¹Ì³ë»ê º¯È ¹× ±âŸ º¯ÀÌ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¾÷µ¥ÀÌÆ®¸¦ Æ÷ÇÔÇÑ´Ù.
±×¸² 2). COVID-19 cases per 100 000 population reported by countries, territories and areas, 28 June – 4 July 2021
Ç¥ 1. WHO Áö¿ªº° COVID-19 ½Å±Ô È®ÁøÀÚ ¹× »ç¸ÁÀÚ ÇöȲ
*Percent change in the number of newly confirmed cases/deaths in the past seven days, compared to seven days prior. **See Annex: Data, table and figure notes (Source: WHO Weekly COVID-19 Update as of 6 July 2021)
±×¸² 3. COVID-19 deaths per 100 000 population reported by countries, territories and areas, 28 June – 4 July 2021
º¯ÀÌ ¹ÙÀÌ·¯½º ¾÷µ¥ÀÌÆ®
(Special Focus: Update on SARS-CoV-2 Variants of Interest and Variants of Concern)
¼¼°èº¸°Ç±â±¸(WHO)´Â ±¹°¡ ´ç±¹, ±â°ü ¹× ¿¬±¸ÀÚµé°ú Çù·ÂÇÏ¿© SARS-CoV-2ÀÇ º¯ÀÌ ¹ÙÀÌ·¯½º°¡ °¨¿°È®»ê, Áúº´ ½É°¢¼ºÀ» º¯°æÇÏ´ÂÁö¸¦ ¸ð´ÏÅ͸µÇÏ°í ±¹°¡µéÀÇ °øÁߺ¸°ÇÁ¤Ã¥ ¹× »çȸÁ¶Ä¡ (PHSM)¿¡¼ ¹é½Å, Ä¡·á, Áø´Ü È¿°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö Á¤±âÀûÀ¸·Î Æò°¡ÇÏ°í ÀÖ´Ù.
±×¸² 4) COVID-19 ¾ËÆÄ, º£Å¸, °¨¸¶, µ¨Å¸ º¯ÀÌ ¹ÙÀÌ·¯½º Áö¿ªº° ÇöȲ(WHO. as of 6 July 2021)
º¯ÀÌ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¿ì·Á, VOC (Variants of Concern) ¶Ç´Â º¯À̹ÙÀÌ·¯½º¿¡ ´ëÇÑ °ü½É, VOI (Variants of Interest)ÀÇ ½Ã±×³ÎÀº ±Û·Î¹ú °øÁߺ¸°Ç¿¡ ´ëÇÑ À§ÇèÀ» ±¸ºÐÇÏ°í Æò°¡Çϱâ À§ÇÑ ±âÃÊ°¡ µÈ´Ù.
• ¸ð´ÏÅ͸µ ÁßÀÎ º¯ÀÌ¿¡ ´ëÇÑ Á¤ÀÇ¿Í ±âŸ º¯ÀÌ ¹ÙÀÌ·¯½º ¹× ¾Æ¹Ì³ë»ê º¯È
• º¯ÀÌ ¹ÙÀÌ·¯½º ºÐ·ù ¾÷µ¥ÀÌÆ®
• º¯ÀÌ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¿ì·Á, VOC (Variants of Concern)¸¦ º¸°í ÇÑ ±¹°¡ / Áö¿ª Á¤º¸
VOC ¹× VOIÀÇ ¿µÇâ°ú °¨½Ã ¹× ´ëÀÀ ¿ä±¸ »çÇ׿¡ ´ëÇÑ ÀÌÇØ°¡ Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÔ¿¡ µû¶ó WHO´Â Á¤±âÀûÀ¸·Î º¯ÀÌ ¹ÙÀÌ·¯½º ÃßÀ̸¦ °ËÅäÇÏ°í Á¶Á¤ÇÏ°í ÀÖ´Ù.
Ç¥ 2. SARS-CoV-2 º¯ÀÌ ¹ÙÀÌ·¯½º ÀÛ¾÷ Á¤ÀÇ, 7¿ù 6ÀÏ ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ÀÚ·á
¿ì·Á º¯ÀÌ(Variant of Concern)
|
VOIÀÇ Á¤ÀǸ¦ ÃæÁ·ÇÏ°í ºñ±³ Æò°¡¸¦ ÅëÇÏ¿© ¼¼°è °øÁß º¸°Ç Á߿伺ÀÇ Á¤µµ¿¡¼ ´ÙÀ½ º¯°æ»çÇ× Áß Çϳª ÀÌ»ó °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î ÀÔÁõµÈ SARS-CoV-2 º¯ÀÌ ¹ÙÀÌ·¯½º :
• COVID-19 ¿ªÇÐ °¨¿°¼º Áõ°¡ ¶Ç´Â ÇØ·Î¿î º¯È; ȤÀº
• µ¶¼ºÀÇ Áõ°¡ ¶Ç´Â ÀÓ»óÁúȯ ÃâÇöÀÇ º¯È; ȤÀº
• °øÁß º¸°Ç ¹× »çȸÀû Á¶Ä¡ ¶Ç´Â ÀÌ¿ë°¡´ÉÇÑ Áø´Ü, ¹é½Å, Ä¡·áÁ¦ÀÇ È¿À²¼º °¨¼Ò.
|
°ü½É º¯ÀÌ(Variant of Interest)
|
SARS-CoV-2 º¯ÀÌ ¹ÙÀÌ·¯½º :
• °¨¿°·Â, Áúº´ ÁßÁõµµ, ¸é¿ªÀÌÅ», Áø´Ü ¶Ç´Â Ä¡·á ÀÌÅ»°ú °°Àº ¹ÙÀÌ·¯½º Ư¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµÇ°Å³ª ¾Ë·ÁÁø À¯ÀüÀû º¯È; ±×¸®°í
• ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Áõ°¡ÇÏ´Â »ç·Ê¿Í ÇÔ²² »ó´ëÀû À¯º´·üÀÌ Áõ°¡ ¿©·¯ ±¹°¡¿¡¼ ½É°¢ÇÑ Áö¿ª»çȸ ÀüÆÄ ¶Ç´Â ¿©·¯ COVID-19 Ŭ·¯½ºÅ͸¦ À¯¹ßÇÏ´Â °ÍÀ¸·Î È®ÀεǴ Àü ¼¼°è °øÁß º¸°Ç¿¡ ´ëÇÑ »õ·Î¿î À§ÇèÀ» ³ªÅ¸³»´Â ¸í¹éÇÑ ¿ªÇÐÀû ¿µÇâ.
|
Ãß°¡ ¸ð´ÏÅ͸µ(Alerts for Further Monitoring)
|
¹ÙÀÌ·¯½º Ư¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ÀǽɵǴ À¯ÀüÀû º¯È°¡ ÀÖ´Â SARS-CoV-2 º¯ÀÌÀº ¹Ì·¡ À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö Àִٴ ¡ÈÄ°¡ ÀÖÁö¸¸ Ç¥ÇöÇü ¶Ç´Â ¿ªÇп¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ Áõ°ÅÀÚ·á´Â ÇöÀç±îÁö ¸íÈ®ÇÏÁö ¾ÊÀ¸¹Ç·Î »õ·Î¿î Áõ°Å°¡ ÀÖÀ» ¶§±îÁö ¸ð´ÏÅ͸µÀ» °ÈÇÏ°í Ãß°¡ Æò°¡°¡ ÇÊ¿ä.
|
Ãâó : WHO Tracking SARS-CoV-2 Variants
Ç¥ 3. º¯À̹ÙÀÌ·¯½ºÀÇ Æä³ëƼÇÈ ¿µÇâ(Summary of phenotypic impacts of Variants of Concern)
Ç¥ 4. º¯À̹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¹é½ÅÁ¢Á¾ È¿´É ¿ä¾à
COVID-19 ±¹³» ¹ß»ý ¹× ¹é½ÅÁ¢Á¾ ÇöȲ
Á߾ӹ濪´ëÃ¥º»ºÎ´Â 7¿ù 7ÀϱâÁØÀ¸·Î, ±¹³» ¹ß»ý ½Å±Ô È®ÁøÀÚ´Â 1,168¸í, ÇØ¿ÜÀ¯ÀÔ »ç·Ê´Â 44¸íÀÌ È®ÀεǾî ÃÑ ´©Àû È®ÁøÀÚ ¼ö´Â 162,753¸í(ÇØ¿ÜÀ¯ÀÔ 10,321¸í)À̶ó°í ¹àÇû´Ù. ÀÇ½É½Å°í °Ë»çÀÚ ¼ö´Â 30,786¸í, ¼öµµ±Ç Àӽà ¼±º° °Ë»ç¼Ò °Ë»ç°Ç¼ö´Â 52,243°Ç(È®ÁøÀÚ 295¸í), ºñ¼öµµ±Ç Àӽà ¼±º° °Ë»ç¼Ò °Ë»ç°Ç¼ö´Â 3,306°Ç(È®ÁøÀÚ 3¸í)À¸·Î ÃÑ °Ë»ç °Ç¼ö´Â 86,335°Ç, ½Å±Ô È®ÁøÀÚ´Â ÃÑ 1,212¸íÀÌ´Ù. ½Å±Ô °Ý¸® ÇØÁ¦ÀÚ´Â 740¸íÀ¸·Î ÃÑ 151,500¸í(93.09%)ÀÌ °Ý¸® ÇØÁ¦µÇ¾î, ÇöÀç 9,220¸íÀÌ °Ý¸® ÁßÀÌ´Ù. À§ÁßÁõ ȯÀÚ´Â 155¸í, »ç¸ÁÀÚ´Â 1¸íÀ¸·Î ´©Àû »ç¸ÁÀÚ´Â 2,033¸íÀ¸·Î Ä¡¸í·ü 1.25%À¸·Î ³ªÅ¸³µ´Ù.
Ç¥ 5. ±¹³» Äڷγª-19 ½Å±Ô È®ÁøÀÚ Áö¿ªº° ÇöȲ(7¿ù7ÀÏ ÇöÀç)
±¹³» Äڷγª 19 ¹é½ÅÁ¢Á¾ ÇöȲÀº 7¿ù7ÀÏ ±âÁØÀ¸·Î 1Â÷ ¹é½Å Á¢Á¾Àº 37,666¸íÀ¸·Î ÃÑ 15,439,910¸íÀÌ 1Â÷ Á¢Á¾À» ¹Þ¾Ò°í, ÀÌ Áß 62,770¸íÀÌ Á¢Á¾À» ¿Ï·áÇÏ¿© ÃÑ 5,463,292¸íÀÌ Á¢Á¾À» ¿Ï·áÇÏ¿´´Ù°í ¹àÇû´Ù.
Ç¥ 6. ±¹³» Äڷγª-19 ¹é½Åº° Á¢Á¾ ÇöȲ(7¿ù7ÀÏ ÇöÀç)
[ÃֽŠ¿¬±¸µ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights
Äڷγª19 ¹é½Å È¥ÇÕ-±³Â÷ Á¢Á¾ È¿°ú¿Í ºÎ½ºÅͼ¦?
(Mix-and-Match Approach to Covid Vaccines)
-¾Æ½ºÆ®¶óÁ¦³×Ä« & ÈÀÌÀÚ ±³Â÷Á¢Á¾ È¿°ú-
Covid ¹é½Å¿¡ ´ëÇÑ ¹Í½º ¾Ø ¸ÅÄ¡ ¹æ½Ä (1Â÷ ¹× 2Â÷ Á¢Á¾¿¡ ¼·Î ´Ù¸¥ ºê·£µåÀÇ ¹é½Å »ç¿ë)Àº Äڷγª ÆÒµ¥¹Í ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ È¿°úÀûÀÎ ¿¹¹æÀÌ µÉ ¼ö ÀÖÀ½ÀÌ ¿µ±¹ÀÇ ÇÑ ¿¬±¸¿¡¼ ¹àÇôÁ³´Ù. Äڷγª19 ¹é½Å È¥ÇÕ-±³Â÷ Á¢Á¾ ¿¬±¸°á°ú(Mix-and-Match Approach to Covid Vaccines) [»ó¼¼º¸±â]
“µ¨Å¸ Ç÷¯½º(Delta Plus)” º¯ÀÌ ¹é½ÅÈ¿°ú?
'Delta' Variant Of COVID-19 Mutates Into 'Delta Plus'
Àεµ¿¡¼ óÀ½ ¹ß»ýÇÑ ‘µ¨Å¸’(Delta) º¯ÀÌ ¹ÙÀÌ·¯½ºÀÇ Àü ¼¼°è È®»êÀÌ °Å¼¼Áö°í ÀÖ´Ù. µ¨Å¸º¯ÀÌ´Â Áö³ÇØ 10¿ù Àεµ¿¡¼ óÀ½ º¸°í µÇ¾úÀ¸³ª, ¿µ±¹¿¡¼ óÀ½ ¹ß°ßµÈ ‘¾ËÆÄ’( alpha) ¹öÀü°ú ºñ±³ÇÏ¿© 50ÆÛ¼¾Æ® ÀÌ»óÀÇ °ÇÑ °¨¿°·ÂÀ» ³ªÅ¸³»°í ÀÖ´Ù. ƯÈ÷ µ¨Å¸ º¯ÀÌ ¹ÙÀÌ·¯½º¿Í ºñ±³ÇÏ¸é ‘µ¨Å¸ Ç÷¯½º’ µ¹¿¬º¯ÀÌ´Â ÀüÆÄ·Â »Ó¸¸ ¾Æ´Ï¶ó ¹é½Å¿¡ ´ëÇÑ ³»¼ºÀÌ ´õ °ÇÑ °ÍÀ¸·Î Æò°¡¹Þ°í ÀÖÀ¸¸ç, ‘µ¨Å¸ Ç÷¯½º º¯ÀÌ’°¡ ÀÌ¹Ì Àεµ 3°³ Áö¿ªÀ» Æ÷ÇÔÇÏ¿© ¹Ì±¹, ¿µ±¹, Áß±¹, ÀϺ»±îÁö °¨¿°ÀÌ È®»êµÇ¾î ¹ß»ýÇÏ°í ÀÖ´Ù. [»ó¼¼º¸±â]
¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½Å 3»ó ÀÓ»ó°á°ú(Phase III, Clinical Trial) ¹ßÇ¥ (Latest results put Oxford–AstraZeneca COVID vaccine back on track)
¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½Å °³¹ß»ç´Â ÃÖ±Ù 3¿ù 26ÀÏÀÚ·Î ÇÙ½ÉÀ̵Ǵ ÀÓ»ó 3»ó(Phase III Clinical Trial) ¿¬±¸°á°ú¿¡¼ 76%ÀÇ Äڷγª-19¹é½Å ¿¹¹æÈ¿°ú °á°ú¸¦ ¹ßÇ¥Çß´Ù. À¯·´ÀǾàǰû(EMA)Àº ¹é½ÅÀÇ Ç°Áú, ¾ÈÀü¼º ¹× È¿´É¿¡ ´ëÇÑ µ¥ÀÌÅÍ Æò°¡¸¦ ÅëÇØ, 18¼¼ÀÌ»ó ¼ºÀÎÀ» ´ë»óÀ¸·Î ¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½ÅÁ¢Á¾ ½ÂÀÎÀ» Çã¿ëÇÔÀ» ¹ßÇ¥Çß´Ù. [»ó¼¼º¸±â]
COVID-19 ¼¼°¡Áö Áø´Ü°Ë»ç ºñ±³ : ºñÀεεµ¸» PCR, Ÿ¾× PCR, ½Å¼ÓÇ׿ø°Ë»ç - Three COVID-19 Diagnostic Tests in Korea -
"ºñÀεεµ¸» PCR→Ÿ¾× PCR→½Å¼ÓÇ׿ø°Ë»ç ¼ø ±ÇÀå…°Ë»ç°á°ú Á¤È®µµ Â÷ÀÌ"
¿ì¸®³ª¶ó¿¡¼ ÇöÀç ½ÃÇàµÇ°í ÀÖ´Â ¼¼°¡Áö Äڷγª19 °Ë»çÁø´Ü¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù. Áúº´°ü¸®Ã» Á߾ӹ濪´ëÃ¥º»ºÎ´Â Äڷγª19 Á¤·Êºê¸®Çο¡¼ ¼¼ °¡Áö Äڷγª19 °Ë»ç¹ý¿¡ ´ëÇØ ¼³¸íÇÏ¸é¼ ¹Î°¨µµ(Sensitivity)¿Í ƯÀ̵µ(specificity)¸¦ °ø°³Çß´Ù. Ç¥ÁØ°Ë»ç¹ýÀÎ ºñÀεεµ¸» PCR(½Ç½Ã°£ ¿ªÀü»ç ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ, rRT-PCR, qRT-PCR)Àº ¹Î°¨µµ 98% ÀÌ»ó, ƯÀ̵µ 100%À̸ç Ÿ¾× PCRÀº ¹Î°¨µµ 92%, ƯÀ̵µ 100%´Ù. ¹Ý¸é, ½Å¼ÓÇ׿ø°Ë»ç¹ýÀº ¹Î°¨µµ 90%, ƯÀ̵µ 96%·Î ¼¼ °¡Áö °Ë»ç¹ý Áß °¡Àå ³·´Ù[»ó¼¼º¸±â]
³ëÈÀÇ °üÁ¡¿¡¼ COVID-19 ÀÓ»óÀû ¾ç»ó - COVID-19 ³ëÀΠȯÀÚÀÇ ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·Â
Understanding the Clinical Features of Coronavirus Disease 2019 From the Perspective of Aging: A Systematic Review and Meta-Analysis
-High Inflammatory State and Low Immune Defense of the Aging Patients With COVID-19-
ÀÓ»óÁú¹® :
³ëÀε鿡°Ô Äڷγª19 °¨¿°ÀÌ ´õ¿í À§Çè°ÍÀº ÀþÀº Ãþ¿¡ ºñÇÏ¿© ³·Àº ¸é¿ª¹æ¾î ´É·ÂÀ̳ª ³ôÀº ¿°Áõ»óÅÂ¿Í °ü·ÃÀÌ ÀÖ½À´Ï±î?
¿¬±¸´äº¯ :
³ëÀÎÃþ ȯÀÚÀÇ Ç÷¾×°Ë»ç°á°ú ÀþÀº Ãþ¿¡ ºñÇÏ¿© ¹éÇ÷±¸ÀÇ ³ôÀº °¡º¯¼ºÀ» ³ªÅ¸³»¾ú´Ù. COVID-19 ³ëÀÎȯÀÚÀÇ ½ÇÇè½Ç °á°ú ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·ÂÀ¸·Î COVID-19 ³ëÀÎ Àα¸¿¡¼ COVID-19·Î ÀÎÇÑ Ãë¾à¼º°ú ºÒ¾ÈÁ¤ÇÑ »óŸ¦ ³ªÅ¸³»¾ú´Ù. Ç÷¾×°Ë»ç °á°ú C- ¹ÝÀÀ¼º ´Ü¹éÁú, ÇÁ·Î Ä®½ÃÅä´Ñ ¹× ÀÎÅÍ·çŲ -6 (C-reactive protein, procalcitonin, and interleukin-6) Åë°è ºÐ¼®À» ¼öÇàÇÏ¿© ³ëÀΠȯÀÚÀÇ ¿°Áõ ¹× ¸é¿ª ¹ÝÀÀÀ» Ãß·ÐÇÏ°í Ç÷¼ÒÆÇ°ú D-dimer¸¦ °è»êÇÏ¿© ³ëÀΠȯÀÚÀÇ ÀÀ°í±â´ÉÀ» È®ÀÎÇÏ¿´´Ù[»ó¼¼º¸±â]
[NEJM] ÈÀÌÀÚ & ¹ÙÀÌ¿À¿£Å×Å© COVID-19 ¹é½Å(Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine) ÀÓ»ó°á°ú ¹× ºÎÀÛ¿ë ¹ßÇ¥
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
¹Ì±¹ Á¦¾àȸ»ç ÈÀÌÀÚ¿Í µ¶ÀÏ »ý¸í°øÇбâ¾÷ ¹ÙÀÌ¿À¿£Å×Å©(BioNTech SE)´Â mRNA ±â¹Ý Äڷγª19 ¹é½Å Èĺ¸¹°Áú ‘BNT162b2’ÀÇ ÀÓ»ó 3»ó ½ÃÇè¿¡¼ µµÃâµÈ ¾ÈÀü¼º ¹× È¿´É¼º °á°ú¿¡ ´ëÇØ ÀÇÇÐ ÇмúÁö ‘´º À×±Û·£µå Àú³Î ¿Àºê ¸Þµð½¼’(NEJM)¿¡ °ÔÀçµÆ´Ù°í 10ÀÏÀÚ·Î ¹ßÇ¥Çß´Ù[»ó¼¼º¸±â].
COVID-19 ȯÀÚÀÇ Ä¡¸íÀ², ÀÓ»óƯ¼º, Åð¿øÀ²
COVID?19 patients' clinical characteristics, discharge rate, and fatality rate of meta?analysis
ÀÌ ¿¬±¸´Â COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î COVID-10ȯÀÚÀÇ Åð¿ø·ü ¹× »ç¸Á·üÀ» ºÐ¼®ÇϱâÀ§ÇØ 2019 ³â 12 ¿ùºÎÅÍ 2020 ³â 2 ¿ù±îÁö COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅÍ´Â 4 °³ÀÇ µ¥ÀÌÅͺ£À̽º¿¡¼ °Ë»öÇÏ¿´´Ù. COVID-19 ȯÀÚÀÇ ÀÓ»ó Áõ»ó°ú °Ë»ç½Ç °á°ú¸¦ Åë°èÀûÀ¸·Î ºÐ¼®ÇÏ°í ´ÜÀÏ ±º ¸ÞŸ ºÐ¼®À¸·Î Åð¿øÀ² °ú »ç¸Á·üÀ» ¼³¸íÇß´Ù. 10°³ÀÇ ¹®Çå¿¡¼ 1994 ³â ȯÀÚÀÇ ÀÌ¿ë °¡´ÉÇÑ µ¥ÀÌÅÍ°¡ ¿¬±¸¿¡ Æ÷ÇԵǾú´Ù. [»ó¼¼º¸±â]
Source: Johns Hopkins University CSSE COVID 19 Data-Last Updated 8 December, 21:06 (London time)
[JAMA] COVID-19 °¨¿°µÈ »ê¸ð¿¡¼ ÅÂ¾î³ ½Å»ý¾Æ´Â COVID-19 Ç×üº¸À¯ (Antibodies in Infants Born to Mothers With COVID-19 Pneumonia)
JAMA¿¡ ¹ßÇ¥µÈ À̹ø ¿¬±¸´Â COVID-19°¡ È®Áø µÈ 6 ¸íÀÇ ÀÓ»êºÎ¿Í ½Å»ý¾Æ¿¡°Ô »õ·Î¿î Ç÷ûÇÐÀû ±âÁØÀ¸·Î ½Å»ý¾Æ °¨¿°¿¡ ´ëÇÑ º¸´Ù ÀÚ¼¼ÇÑ Á¶»ç ±âÁØÀ» Àû¿ëÇؼ COVID-19¿¡ °¨¿°µÈ ¸ð¼º¿¡°Ô¼ ÅÂ¾î³ ½Å»ý¾ÆÀÇ COVID-19 Ç×ü º¸À¯¿¡ ´ëÇÑ ¿¬±¸¸¦ ¼öÇàÇÏ¿´´Ù. [»ó¼¼º¸±â]
COVID-19 Vaccines ºñ±³: ÈÀÌÀÚ(Pfizer & BioNTech), ¸ð´õ³ª(Moderna) & ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)
¹Ì±¹ ÈÀÌÀÚ¿Í µ¶ÀÎ ¹ÙÀÌ¿À¿£Å×Å©(Pfizer & BioNTech) °³¹ßÇÑ COVID-19 ¹é½Å°ú ¹Ì±¹ ¸ð´õ³ª(Moderna) Á¦¾àȸ»çÀÇ ¹é½Å °³¹ß ¹ßÇ¥¿¡ À̾î, ¿µ±¹°è ´Ù±¹Àû Á¦¾à»ç ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)´Â 23ÀÏ Èıâ ÀÓ»ó½ÃÇè¿¡¼ 90% È¿°ú°¡ ÀÖ´Â °·ÂÇÑ COVID-19 ¹é½ÅÀÇ ÀÓ»ó½ÃÇè °á°ú¸¦ ÀÕ´Þ¾Æ ¹ßÇ¥Çß´Ù. ÀÌÁ¦ Àü¼¼°è´Â Äڷγª19 °¨¿°À» µåµð¾î ³¡³¾ ¹é½ÅÀÌ °³¹ßµÈ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ´Ù. [»ó¼¼º¸±â]
NIH- Remdesivir (·½µ¥½Ãºñ¸£) COVID-19 Ä¡·áÁ¦·Î ½ÂÀÎ
¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¿ø(NIH)ÀÌ ¼öÇàÇÑ Ç×¹ÙÀÌ·¯½º ·½µ¥½Ãºñ¾î(remdesivir) ÀÓ»ó½ÃÇ迬±¸ °á°ú°¡ NEJM (New England Journal of Medicine.)À» ÅëÇØ ¹ßÇ¥µÇ¾ú´Ù. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home)
ÀÌ °á°ú¸¦ ±Ù°Å·Î 5¿ù 1ÀÏ¿¡ ¹Ì±¹ FDA(½Ä¾àó)´Â ·½µ¥½Ãºñ¾î¸¦ ¡¸ÁßÁõ¡¹È¯ÀÚ(»ê¼ÒÆ÷ȵµ <94%, »ê¼Ò Ä¡·á ÇÊ¿ä)¿¡°Ô ±ä±Þ»ç¿ëÇã°¡¸¦ ½ÂÀÎÇÏ¿´À¸¸ç, ÀÌÁ¦ ·½µ¥½Ãºñ¾î°¡ COVID-19ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î »ç¿ëÇã°¡µÇ¾ú´Ù. [»ó¼¼º¸±â]
[±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma)
±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]
COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù. [»ó¼¼º¸±â]
NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]
º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á- Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù.
º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.
1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)
2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)
3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79)
4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)
5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40)
6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)
¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]
COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ
ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]
Ç¥ 3) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü COVID -19 ÃֽŠÁ¤º¸ ¹Ù·Î°¡±â
Ç¥ 6) Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC) Á¦°ø
* º» ³»¿ëÀº MedRIC (www.medric.or.kr)ÀÇ ¿¬±¸µ¿Çâ¿¡¼ ¼ºñ½ºµÇ´Â ³»¿ëÀÔ´Ï´Ù.
References
Çѱ¹ : Á߾ӹ濪´ëÃ¥º»ºÎ Á¤·Êºê¸®ÇÎ(7¿ù7ÀÏÀÚ) ÀÚ·á
WHO: Weekly epidemiological update on COVID-19 - 6 July 2021
Áß±¹ : ±¹°¡À§»ý°Ç°À§¿øȸ ȨÆäÀÌÁö
ÀÌÅ»¸®¾Æ : º¸°ÇºÎ ȨÆäÀÌÁö
ÀϺ» : ÈÄ»ý³ëµ¿¼º º¸µµÀÚ·á
¿µ±¹ : Á¤ºÎ»çÀÌÆ®
¹Ì±¹ : Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE